Abstract:  Ovarian cancer is a common malignant cancer of the female reproductive system. It is usually diagnosed at a late stage and thus becomes the most lethal gynecological maligancy. Therefore, finding specific molecular biomarkers and effective molecular targets is of great significance for the diagnosis, evaluation of the therapy effect and prognosis of ovarian cancer. Studies have shown that epigenetic modification plays a key role in the development of ovarian cancer. The histone methyltransferase enhancer of zeste homolog 2(EZH2) is the enzymatic catalytic subunit of the polycomb repressive complex 2 (PRC2) and is commonly involved in transcriptional repression by trimethylating lysine 27 on histone 3 (H3K27). EZH2 plays a pivotal role in many biological processes such as cell apoptosis, cell cycle, and cell differentiation. In ovarian cancer, EZH2 is significantly overexpressed and the high expression of EZH2 in ovarian malignant tumors is closely related with the poor prognosis of patients. In addition, as an epigenetic modifier, EZH2 affects biological behaviors such as cell proliferation, metastasis and drug resistance of ovarian cancer cells and plays a crucial role in regulating tumor progression. Therefore, EZH2 may provide a new effective target for the treatment of ovarian malignancies. 

Key words: Enhancer of zeste homolog 2 protein；, Ovarian neoplasms；, Epigenesis, genetic；, Cell proliferation；, Therapy